Skip to content
PharmAlert — Clinical Decision Support

PLATFORM

What PharmAlert checks, and how it decides.

Six categories of clinical risk, evaluated against the patient the prescription is written for. Every finding carries its reason, its evidence and — where one exists — a safer alternative.

What PharmAlert checks

DRUG INTERACTIONS
Interactions are assessed against the patient's other medicines and their own clinical picture. The same pairing does not carry the same risk in a healthy 30-year-old and an 82-year-old with reduced renal function, and PharmAlert does not present it as though it does.
DOSE APPROPRIATENESS
Doses are checked against renal and hepatic function, age, weight where available, and licensed ranges — with the threshold that triggered the finding shown alongside it.
CONTRAINDICATIONS
Pregnancy, breastfeeding, allergy, and existing conditions are treated as hard clinical context, not optional fields. Where a medicine should not be used, PharmAlert says so plainly and suggests what to consider instead.
DUPLICATE THERAPY
Two medicines from the same class, prescribed across different episodes or by different clinicians, are one of the easiest errors to miss and one of the easiest to catch.
POLYPHARMACY
Beyond a certain number of medicines, the risk stops being about any single pairing. PharmAlert flags when a structured review is likely to be more useful than another individual alert.
RISK PRIORITISATION
Every finding is ranked by clinical significance and patient context, so the alert that matters is the one at the top — not the one that happened to fire first.

Dose appropriateness · try it

DOSE APPROPRIATENESS

WarningPA-DOS-003

Metformin · eGFR 30–44

At this level of renal function the maximum metformin dose is reduced, typically to 1 g daily in divided doses.

Well documented · Established

SuggestedReduce the dose and review renal function every three to six months — confirm against local guidance.

Demonstration only, using fictional patients. Not for clinical use.

Contraindications · try it

CONTRAINDICATIONS

CriticalPA-CON-002

ACE inhibitor · pregnancy

ACE inhibitors cause fetal renal injury, oligohydramnios and skeletal defects, particularly in the second and third trimesters.

Well documented · Established

SuggestedLabetalol or nifedipine are usual alternatives in pregnancy — confirm against local obstetric guidance.

Demonstration only, using fictional patients. Not for clinical use.

What we don't do

PharmAlert does not prescribe.

PharmAlert does not override clinical judgement.

PharmAlert is not a substitute for a full medication review.

PharmAlert does not replace your local formulary or national guidance.

See it running against your own case mix.

Tell us about your setting and we will come back with what a pilot would look like.

Request a pilot